The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase I study of LY2127399, a human anti-BAFF antibody, and bortezomib in patients with previously treated multiple myeloma.
N. S. Raje
No relevant relationships to disclose
R. J. Hohl
Research Funding - Lilly
E. A. Faber
Consultant or Advisory Role - Millennium
P. G. G. Richardson
Consultant or Advisory Role - Bristol-Myers Squibb; Celgene; Johnson & Johnson; Millennium; Novartis
A. Forero-Torres
Research Funding - Lilly
G. J. Schiller
Research Funding - Lilly
A. D. Cohen
Consultant or Advisory Role - Celgene; Millennium; Onyx
Honoraria - Celgene
S. P. Carpenter
Employment or Leadership Position - Lilly
D. Cronier
Employment or Leadership Position - Lilly
Stock Ownership - Lilly
M. Pashkevich
Employment or Leadership Position - Lilly
Stock Ownership - Lilly
J. Wooldridge
Employment or Leadership Position - Lilly
Stock Ownership - Lilly
K. C. Anderson
Consultant or Advisory Role - Bristol-Myers Squibb; Celgene; Merck; Millennium; Novartis; Onyx